Client Neomorph Collaborates With AbbVie to Develop Novel Molecular Glue Degraders for Up to $1.6 Billion
January 25, 2025
January 25, 2025
BOSTON, Massachusetts, Jan. 25 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised biotechnology company Neomorph in a collaboration and option-to-license agreement with AbbVie to develop novel molecular glue degraders for multiple targets across oncology and immunology.
Molecular glue degraders are a novel class of small molecules that are designed to selectively target and trigger degradation of proteins that drive cancer growth or immun . . .
Ropes & Gray advised biotechnology company Neomorph in a collaboration and option-to-license agreement with AbbVie to develop novel molecular glue degraders for multiple targets across oncology and immunology.
Molecular glue degraders are a novel class of small molecules that are designed to selectively target and trigger degradation of proteins that drive cancer growth or immun . . .